Prospects and challenges of CRISPR/Cas9 gene-editing technology in cancer research

被引：3

作者：

Ning, Li ^{[1
,2
]}

Xi, Jiahui ^{[1
,2
]}

Zi, Yin ^{[1
,2
]}

Chen, Min ^{[1
,2
]}

Zou, Qingjian ^{[1
,2
]}

Zhou, Xiaoqing ^{[1
,2
]}

Tang, Chengcheng ^{[1
,2
]}

机构：

[1] Wuyi Univ, South China Inst Large Anim Models Biomed, Sch Biotechnol & Hlth Sci, Guangdong Prov Key Lab Large Anim Models Biomed, Jiangmen 529000, Peoples R China

[2] Int Healthcare Innovat Inst Jiangmen, Jiangmen, Peoples R China

来源：

CLINICAL GENETICS | 2023年 / 104卷 / 06期

关键词：

cancer; gene-editing; CRISPR/Cas9; gene therapy; immunotherapy; T-CELLS; CAS9; RIBONUCLEOPROTEIN; GENOMIC DNA; DELIVERY; BASE; IDENTIFICATION; BACTERIA; EFFICACY; REPEATS; SYSTEMS;

D O I：

10.1111/cge.14424

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Cancer, one of the leading causes of death, usually commences and progresses as a result of a series of gene mutations and dysregulation of expression. With the development of clustered regularly interspaced palindromic repeat (CRISPR)/Cas9 gene-editing technology, it is possible to edit and then decode the functions of cancer-related gene mutations, markedly advance the research of biological mechanisms and treatment of cancer. This review summarizes the mechanism and development of CRISPR/Cas9 gene-editing technology in recent years and describes its potential application in cancer-related research, such as the establishment of human tumor disease models, gene therapy and immunotherapy. The challenges and future development directions are highlighted to provide a reference for exploring pathological mechanisms and potential treatment protocols of cancer.

引用

页码：613 / 624

页数：12

共 75 条

[1] Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management
Allemailem, Khaled S.
Alsahli, Mohammed A.
Almatroudi, Ahmad
Alrumaihi, Faris
Alkhaleefah, Fahd Khaleefah
Rahmani, Arshad Husain
Khan, Amjad Ali
[J]. CANCER COMMUNICATIONS, 2022, 42 (12) : 1257 - 1287
[2] Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors
Anzalone, Andrew V.
Koblan, Luke W.
Liu, David R.
[J]. NATURE BIOTECHNOLOGY, 2020, 38 (07) : 824 - 844
[3] Search-and-replace genome editing without double-strand breaks or donor DNA
Anzalone, Andrew V.
Randolph, Peyton B.
Davis, Jessie R.
Sousa, Alexander A.
Koblan, Luke W.
Levy, Jonathan M.
Chen, Peter J.
Wilson, Christopher
Newby, Gregory A.
Raguram, Aditya
Liu, David R.
[J]. NATURE, 2019, 576 (7785) : 149 - +
[4] An Integrated Genome-wide CRISPRa Approach to Functionalize lncRNAs in Drug Resistance
Bester, Assaf C.
Lee, Jonathan D.
Chavez, Alejandro
Lee, Yu-Ru
Nachmani, Daphna
Vora, Suhani
Victor, Joshua
Sauvageau, Martin
Monteleone, Emanuele
Rinn, John L.
Provero, Paolo
Church, George M.
Clohessy, John G.
Pandolfi, Pier Paolo
[J]. CELL, 2018, 173 (03) : 649 - +
[5] Hydrodynamic Gene Delivery and Its Applications in Pharmaceutical Research
Bonamassa, Barbara
Hai, Li
Liu, Dexi
[J]. PHARMACEUTICAL RESEARCH, 2011, 28 (04) : 694 - 701
[6] Long-term outcomes following CAR T cell therapy: what we know so far
Cappell, Kathryn M.
Kochenderfer, James N.
[J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2023, 20 (06) : 359 - 371
[7] Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Cherkassky, Leonid
Morello, Aurore
Villena-Vargas, Jonathan
Feng, Yang
Dimitrov, Dimiter S.
Jones, David R.
Sadelain, Michel
Adusumilli, Prasad S.
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (08) : 3130 - 3144
[8] Chow Jonathan Tak-Sum, 2020, Fac Rev, V9, P31, DOI 10.12703/r/9-31
[9] Adenovirus: The First Effective In Vivo Gene Delivery Vector
Crystal, Ronald G.
[J]. HUMAN GENE THERAPY, 2014, 25 (01) : 3 - 11
[10] CRISPR gene editing tested in a person
Cyranoski, David
[J]. NATURE, 2016, 539 (7630) : 479 - 479

← 1 2 3 4 5 6 7 8 →